Merck & Co. Inc. (NYSE:MRK) on Tuesday announced the discontinuation of the clinical development program evaluating nemtabrutinib (MK-1026), an investigational, oral, non-covalent Bruton's tyrosine kinase (BTK) inhibitor.
Nemtabrutinib is being evaluated for patients with chronic lymphocytic leukemia (CLL), small lymphocytic leukemia (SLL), and other hematologic malignancies in the BELLWAVE program.
Discontinued the Phase 3 BELLWAVE Trials
Merck is discontinuing the Phase 3 BELLWAVE-011 trial following review of the results by an external Data Monitoring Committee (eDMC) that suggested the benefits may not outweigh the risks in this study.
Merck subsequently confirmed this following a review of the data in its totality.
The company also decided to discontinue the broader BELLWAVE clinical development program, including the other Phase 3 studies: BELLWAVE-008 and BELLWAVE-010.
Terns Pharmaceuticals Deal and Earlier BELLWAVE-001 Data
Merck added the drug through a Terns Pharmaceuticals Inc. deal for $53.00 per share in cash for an approximate equity value of $6.7 billion.
At EHA 2023, Merck presented updated Phase 1/2 results from the BELLWAVE-001 trial, evaluating nemtabrutinib (MK-1026) in B-cell malignancies.
Nemtabrutinib 65 mg once daily (QD) generated a 32% ORR, a 24.4-month mDOR, and a 26.3-month mPFS in CLL/SLL patients.
MRK Price Action: Merck & Co shares were down 2.26% at $140.13 at the time of publication on Wednesday, according to Benzinga Pro data.